Table II.
Inhibitors | PMN Early/Late Apoptosis (% Annexin V+ cells) |
||||
---|---|---|---|---|---|
No Ligand | Fg | Plg | P2-C | P1 | |
No inhibitor | 65.4 ± 15 | 22.4 ± 5 | 22.3 ± 6 | 20.1 ± 4 | 56.1 ± 13 |
MβCD | 55.6 ± 17 | 59.3 ± 15 | 75.0 ± 13 | 75.6 ± 17 | 66.3 ± 18 |
MLCK inhibitor peptide 18 | 70.9 ± 14 | 84 ± 24 | 68.1 ± 16 | 82.0 ± 22 | 65.3 ± 17 |
H7 | 77.6 ± 18 | 62.3 ± 16 | 79.2 ± 18 | 78.6 ± 17 | 60.1 ± 14 |
BDM | 98.9 ± 20 | 98.7 ± 24 | 99.2 ± 24 | 97.8 ± 22 | 85.4 ± 20 |
Cytochalasin D | 58.9 ± 18 | 55.5 ± 18 | 66.6 ± 15 | 77.4 ± 16 | 66.07 ± 15 |
Calpain inhibitor III | 97.3 ± 24 | 88.9 ± 23 | 97.1 ± 22 | 74.7 ± 19 | 94.5 ± 22 |
PMNs were incubated with inhibitors of integrin clustering pathways and various αMβ2 ligands (proteins at 1 μM, peptides at 100 μM) as indicated for 16 h at 37°C. The data represent means ± SEM (n = 5).